文献速递临床试验与 GCP流行病学与生物统计

序贯整合治疗的贝叶斯最优适应性临床试验设计

A Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies.
PubMed 文献 · Stat Med · 2026-01-01

针对需序贯整合多种治疗的复杂疾病(如酒精相关肝炎),提出基于贝叶斯模型的BIT试验设计,连接急性期与后续治疗阶段结局,采用多重期中分析与自适应停止规则控制I类错误并最大化统计效能,模拟显示良好操作特性,并提供R代码。

要点

  • BIT设计通过贝叶斯模型连接急性期与后续治疗阶段结局,适用于序贯整合治疗评估。
  • 采用多重期中分析与无效性/优效性自适应停止规则,控制family-wise I类错误率并最大化统计效能。
  • 以重型酒精相关肝炎整合治疗试验为例展示样本量确定与设计参数优化,模拟显示良好操作特性。

核心结论

  • BIT设计为需序贯整合多种治疗的复杂疾病提供了一种高效且能控制I类错误的适应性试验框架。

研究设计与样本

  • 基于贝叶斯模型的适应性设计,连接急性期与后续治疗阶段结局,纳入多重期中分析及无效性与优效性自适应停止规则。

主要发现

  • 模拟研究显示该设计具有优良的操作特性,包括控制实验-wise I类错误率。
  • 以重型酒精相关肝炎整合治疗临床试验为例,完成了样本量确定与设计参数优化。

临床怎么用

  • 可用于评估需序贯整合治疗的复杂疾病(如重型酒精相关肝炎)的最优治疗组合。
  • 提供R代码供BIT设计实施,便于研究者应用。

局限性

  • 设计开发虽以酒精相关肝炎治疗研究为动机,但框架可广泛适用于其他需序贯治疗给药的复杂疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical syndromes or diseases with complex etiology often require multiple treatments, each addressing one specific aspect of the disease. Such treatments are typically administered sequentially in an integrated fashion. For example, in alcohol-associated hepatitis (AH), an acute liver disease caused by excessive alcohol drinking, successful treatment requires therapies that reduce liver inflammation during the acute phase, followed by interventions that address the underlying alcohol use disorder (AUD) to achieve optimal outcomes. Selecting an optimal treatment combination, however, presents great challenges in study design due to the involvement of multiple drug combinations and treatment phases. In this paper, we describe a new trial design based on a Bayesian model that connects the outcomes from the acute and subsequent treatment phases. We refer to this design as the Bayesian Optimal Adaptive Design for Sequentially Integrated Therapies (BIT) design. BIT incorporates multiple interim analyses with adaptive stopping rules for both futility and superiority, enhancing efficiency while controlling the family-wise type I error rate and maximizing statistical power. We illustrate the use of BIT design in a clinical trial comparing the efficacy of integrated therapy for severe AH, with sample size determination and design parameter optimization. Simulation studies show that the design possesses excellent operating characteristics, including experiment-wise type I error rate control. Although the design's development is motivated by studies of AH treatment, the design framework is broadly applicable to other complex diseases requiring sequentially delivered therapies. R codes are provided for BIT implementation.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Li Y, Guo J, Gawrieh S, et al. A Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies. Stat Med. 2026. PMID: 42530482. doi:10.1002/sim.70684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。